Medicine and Dentistry
Breast Cancer
100%
Neoplasm
73%
Positron Emission Tomography
48%
Positron Emission Tomography
41%
Metastatic Breast Cancer
29%
Estrogen Receptor
27%
Molecular Imaging
24%
Radioactive Tracer
24%
Gamma Urogastrone
24%
Zirconium 89
23%
Diethylstilbestrol
19%
Trastuzumab
18%
Epidermal Growth Factor Receptor 2
17%
Malignant Neoplasm
16%
Biological Marker
16%
Bevacizumab
15%
Metastatic Carcinoma
14%
Male Breast Cancer
14%
Fluorine-18
12%
Biodistribution
11%
Positron Emission Tomography-Computed Tomography
10%
Recurrent Disease
10%
Clinical Trial
10%
Androgen Receptor
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
Disease
9%
Ovarian Cancer
8%
Vasculotropin A
8%
Cancer Therapy
7%
Receptor Expression
7%
16alpha Fluoroestradiol F 18
7%
Luminespib
7%
Symptom
7%
Hormone Therapy
7%
Vasculotropin
6%
Fluorodeoxyglucose F 18
6%
Immunohistochemistry
6%
T Cell
6%
Tumor Xenograft
6%
Oncology
5%
Quality of Life
5%
Overall Survival
5%
Treatment Response
5%
Cancer Cell
5%
Hazard Ratio
5%
Triple Negative Breast Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
59%
Breast Cancer
55%
Zirconium 89
23%
Gamma Urogastrone
17%
Metastatic Breast Cancer
17%
Trastuzumab
16%
Epidermal Growth Factor Receptor 2
14%
Biological Marker
13%
Bevacizumab
13%
Tracer
12%
Biodistribution
12%
Malignant Neoplasm
10%
Estrogen Receptor
9%
Recurrent Disease
8%
Monoclonal Antibody
7%
Endocrine Therapy
7%
Luminespib
7%
Clinical Trial
7%
Fluorine 18
7%
Diethylstilbestrol
6%
Vasculotropin A
6%
Chemotherapy
5%
Mouse
5%
Keyphrases
Positron Emission Tomography
11%
Metastatic Breast Cancer
10%
Breast Cancer
8%
Fluoro
7%
17-estradiol
7%
Molecular Imaging
7%
Male Breast Cancer
6%
Tumor
6%
18F-FES
5%
89Zr-trastuzumab
5%
Breast Cancer Patients
5%
Human Epidermal Growth Factor Receptor 2 (HER2)
5%
HER2-positive Breast Cancer
5%
18F-FES PET
5%
Positron Emission Tomography-computed Tomography (PET-CT)
5%
